Medical College of Georgia, Augusta, GA.
Department of Pathology, Texas Tech University Health Sciences Center, Lubbock, TX.
Clin Lung Cancer. 2023 Nov;24(7):573-580. doi: 10.1016/j.cllc.2023.08.003. Epub 2023 Aug 5.
The under-representation of racial, sexual, and gender minorities in cancer clinical trials has long been a deficit in clinical cancer research. This review aims to survey current literature to determine the participation of minorities in the United States in lung cancer clinical trials and to find educational methods that have been studied and researched in order to improve patient clinical trial enrollment. A literature search of relevant articles published since 2015 was conducted using PubMed and Google Scholar. Clinical trials conducted in the United States from Clinicaltrials.gov were also collected to determine minority patient enrollment in lung cancer clinical trials. The results of the literature search yielded 6 relevant articles about racial minority representation in lung cancer clinical trials and one relevant article about LGBTQ+ minority representation in cancer clinical trials. Collectively, the literature highlighted the under-representation of racial minorities (such as Black, Hispanic, and American Indian) in clinical trials. Many articles showed that disparities in enrollment were less significant for Asian patients with lung cancer. However, many articles did not mention minorities like Middle Eastern/North Africans and failed to mention the lack of distinguishment of South Asian minorities from Pacific Asian minorities. The findings of this literature review support the idea that current lung cancer clinical trials lack representation of minority patient populations in the United States. The inclusion of racial, sexual, and gender diversity in clinical trial patient populations will aid providers in determining appropriate therapeutics and could potentially improve lung cancer outcomes. Future directions for improving diversity in lung cancer clinical trial enrollment include the utilization of various educational tools to increase minority patient participation in trials, the inclusion of detailed demographic data in cancer clinical trial analysis, and the recruitment of providers and research staff from various minorities to conduct cancer clinical trials.
癌症临床试验中少数族裔、性别和性少数群体代表性不足一直是临床癌症研究的一个缺陷。本综述旨在调查当前文献，以确定少数族裔参与美国肺癌临床试验的情况，并找到已研究和研究过的教育方法，以提高患者参与临床试验的比例。使用 PubMed 和 Google Scholar 对 2015 年以来发表的相关文章进行了文献检索。还从 Clinicaltrials.gov 收集了在美国进行的临床试验，以确定肺癌临床试验中少数族裔患者的入组情况。文献检索的结果产生了 6 篇关于肺癌临床试验中少数族裔代表性的相关文章和 1 篇关于癌症临床试验中 LGBTQ+少数族裔代表性的相关文章。总的来说，这些文献强调了少数族裔（如黑人、西班牙裔和美洲印第安人）在临床试验中代表性不足。许多文章表明，肺癌亚洲患者的入组差异较小。然而，许多文章没有提到中东/北非裔等少数族裔，也没有提到南亚裔和太平洋裔少数族裔之间缺乏区别。本文献综述的结果支持这样一种观点，即目前的肺癌临床试验在美国缺乏少数族裔患者群体的代表性。在临床试验患者群体中纳入种族、性别和性别多样性将有助于提供者确定合适的治疗方法，并有可能改善肺癌的结果。提高肺癌临床试验入组多样性的未来方向包括利用各种教育工具来增加少数族裔患者参与试验、在癌症临床试验分析中纳入详细的人口统计数据，以及招募来自不同少数民族的提供者和研究人员来开展癌症临床试验。
